## Disclosures

### Personal Commercial (9)

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Relationship Category</th>
<th>Compensation Level</th>
<th>Topic Area(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Self</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abiomed</td>
<td>Consultant Fees/Honoraria</td>
<td>Significant (≥ $5,000)</td>
<td>Invasive CV Angio and Interventions</td>
</tr>
<tr>
<td>Accumed Radial Systems</td>
<td>Ownership Interest/Partnership/Principal</td>
<td>Modest (&lt; $5,000)</td>
<td>Invasive CV Angio and Interventions</td>
</tr>
<tr>
<td>Astra Zeneca</td>
<td>Consultant Fees/Honoraria</td>
<td>Significant (≥ $5,000)</td>
<td>Acute Coronary Syndromes General Cardiology</td>
</tr>
<tr>
<td>Esperion</td>
<td>Consultant Fees/Honoraria</td>
<td>Modest (&lt; $5,000)</td>
<td>Prevention</td>
</tr>
<tr>
<td>Medtronic</td>
<td>Consultant Fees/Honoraria</td>
<td>Significant (≥ $5,000)</td>
<td>Invasive CV Angio and Interventions</td>
</tr>
<tr>
<td>Merit Medical</td>
<td>Consultant Fees/Honoraria</td>
<td>Significant (≥ $5,000)</td>
<td>Invasive CV Angio and Interventions</td>
</tr>
<tr>
<td>NHLBI</td>
<td>Research/Research Grants</td>
<td>Significant (≥ $5,000)</td>
<td>Other</td>
</tr>
<tr>
<td>Terumo Medical</td>
<td>Consultant Fees/Honoraria</td>
<td>Modest (&lt; $5,000)</td>
<td>Invasive CV Angio and Interventions</td>
</tr>
<tr>
<td>Zoll</td>
<td>Consultant Fees/Honoraria</td>
<td>Modest (&lt; $5,000)</td>
<td>Invasive CV Angio and Interventions</td>
</tr>
</tbody>
</table>

### Personal Organizational or Other Non-Commercial (1)

<table>
<thead>
<tr>
<th>Non-Commercial Entity Name</th>
<th>Relationship Category</th>
<th>Compensation Level</th>
<th>Topic Area(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Self</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>American Heart Association</td>
<td>Other - Past-Chair, Acute Care Committee</td>
<td>None ($0)</td>
<td>Acute Coronary Syndromes Other</td>
</tr>
</tbody>
</table>

### Clinical Trial Enroller (11)

<table>
<thead>
<tr>
<th>Trial Name</th>
<th>Trial Sponsor</th>
<th>Trial Funding Source</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PHP SHIELD II</strong></td>
<td>Abbott Laboratories</td>
<td></td>
</tr>
<tr>
<td>Jostent GraftMaster RX Coronary Stent Graft System Humanitarian Use Device</td>
<td>Abbott Vascular</td>
<td></td>
</tr>
<tr>
<td>Galileo</td>
<td>Bayer Healthcare Pharmaceuticals</td>
<td></td>
</tr>
<tr>
<td>REPRISE III</td>
<td>Boston Scientific</td>
<td></td>
</tr>
<tr>
<td>EVOLVE II</td>
<td>Boston Scientific</td>
<td></td>
</tr>
<tr>
<td>Carillon</td>
<td>Cardiac Dimensions, Inc.</td>
<td></td>
</tr>
<tr>
<td><strong>SAFE STEMI for SENIORS</strong></td>
<td>Duke Clinical Research Institute</td>
<td>Medtronic, Terumo Medical</td>
</tr>
<tr>
<td>Liraglutide effects on Epicardial Fat Genes</td>
<td>Novo Nordisk Inc.</td>
<td></td>
</tr>
<tr>
<td>Scoreflex</td>
<td>OrbusNeich</td>
<td></td>
</tr>
<tr>
<td>Optimize</td>
<td>Svelte</td>
<td></td>
</tr>
<tr>
<td><strong>RELIEVE-HF</strong></td>
<td>V-Wave, Inc.</td>
<td></td>
</tr>
</tbody>
</table>
Expert Witness Testimony (1)

<table>
<thead>
<tr>
<th>Year</th>
<th>Case Title</th>
<th>Represented</th>
<th>Description</th>
<th>Compensation</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>Sudden cardiac death post-myocardial infarction</td>
<td>Defendant</td>
<td></td>
<td>Modest (&lt; $5,000)</td>
</tr>
</tbody>
</table>

Agreement

Certified Education Attestation | Signed on 7/23/2020
URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 7/23/2020
URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 7/23/2020
URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 7/23/2020

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.